Summary of HILL-ROM HOLDINGS, INC.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward-Looking Statements and Factors That May Affect Future Results Certain statements in this Quarterly Report on Form 10-Q ("Form 10-Q") contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future plans, objectives, beliefs, expectations, representations and projections. We have tried, whenever possible, to identify these forward-looking statements by using words such as "intend," "anticipate," "believe," "plan," "encourage," "expect," "may," "goal," "become," "pursue," "estimate," "strategy," "will," "projection," "forecast," "continue," "accelerate," "promise," "increase," "higher," "lower," "reduce," "improve," "expand," "progress," "potential" or the negative of those terms or other variations of them or by comparable terminology. The absence of such terms, however, does not mean that the statement is not forward-looking. We caution readers that any such forward-looking statements are based on assumptions that we believe are reasonable, but are subject to a wide range of risks. It is important to note that forward-looking statements are not guarantees of future performance, and our actual results could differ materially from those set forth in any forward-looking statements. There are a number of factors - many of which are beyond our control - that could cause actual conditions, events or results to differ significantly from those described in the forward-looking statements. For a more in depth discussion of the factors that could cause actual results to differ from those contained in forward-looking statements, see the discussions under the heading "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 ("2008 Form 10-K") as filed with the United States Securities and Exchange Commission ("SEC"), as well as the discussions in this "Management's Discussion and Analysis". We assume no obligation to update or revise any forward-looking statements. Readers should also refer to the various disclosures made by us in our periodic reports on Form 8-K filed with the SEC. Overview
The following discussion and analysis should be read in conjunction with the accompanying interim financial statements and our 2008 Form 10-K. Hill-Rom Holdings, Inc. (the "Company," "we," "us," or "our") is a leading worldwide manufacturer and provider of medical technologies and related services for the health care industry, including patient support systems, safe mobility and handling solutions, non-invasive therapeutic products for a variety of acute and chronic medical conditions, medical equipment rentals and information technology solutions. Our comprehensive product and service offerings are used by health care providers across the health care continuum in hospitals, extended care facilities and home care settings worldwide, to enhance the safety and quality of patient care.
For a detailed discussion of industry trends, strategy and other factors impacting our businesses, see "Management's Discussion and Analysis of Financial Conditions and Results of Operations - Industry Trends, Strategy and Other Factors Impacting Hill-Rom's Business" in our 2008 Form 10-K. Industry Trends and Strategic Plan
In our 2008 Form 10-K, we described our key strategic initiatives over the 2009-2011 timeframe to support our goals of growing our annual revenue by an average of eight to twelve percent, including six to eight percent through organic means and two to four percent through strategic acquisitions, and growing our annual operating income by an average of twelve to fifteen percent. Since the last half of our first fiscal quarter our progress against these financial objectives has been adversely impacted by unprecedented economic pressures being faced by U.S. hospitals and other health care institutions that have resulted in material reductions in capital spending. Recently, these pressures have shown some signs of easing in the U.S. as customers gain improved access to capital; however the uncertainties of rapidly emerging healthcare reform could result in further pressures on the operating profits of our customers and their purchasing decisions. In addition, during the second half of our second quarter we began to see signs of softening capital expenditures in certain other parts of the world. While we can not predict the significance of the economic impact on domestic and international capital spending, the timing of the economic recovery or when hospitals will return to more normalized capital acquisition behavior, we feel we will be well positioned to resume our predicted long term growth rates in sales and profitability once the underlying fundamentals of demand for our products are restored.

Table of Contents

In response to these uncertainties, we have taken a number of actions to better balance our capacity with demand, as well as to continue to reduce the overall cost structure of our business as outlined below. We remain committed to our new product development efforts and continue to make selective investments in our sales channels. During the third quarter we continued our integration of Liko's product platforms, business processes, engineering capabilities, clinical services and sales channels with our established brands, products, and sales and service organizations across all of our segments and are beginning to realize cost synergies.
Other significant strategic activities undertaken or continuing during the third quarter include:
Differentiate Our Core North America Acute Care Business.
• We have enhanced our sales channels through redeployment of our sales and services resources to increase our presence with customers. In addition, we have also consolidated our therapy and patient support marketing organization to provide greater leverage on our product platforms.

• We have invested in product innovation and research and development in areas that we expect to have a long term return while still addressing our core value propositions to patients and their caregivers. Recent product launches include the Elements™ headwall system, a flexible and adaptable headwall system designed to bring electric power, data and gases to the patient care arena, as well as the VersaCare® P500 wound care surface designed to improve removal of excess heat and moisture from the surface for cooler, dryer skin. In addition, we continue to receive positive feedback with respect to the previously announced launch of our enhanced NaviCare® Clinical Operations Platform, an all digital platform designed to improve communication and keep caregivers in touch with their patients.

• A key element of our strategy over the past 24-36 months continues to be the revitalization of our rental business. Our recent launches of innovative products, including the TotalCare® Bariatric Plus system, VersaCare® P500 wound care surface and Envision® wound therapy product, have yielded revenue growth and margin expansion throughout our fiscal year.

• In April, we announced a strategic development arrangement with TeleTracking Technologies, Inc. ("TeleTracking") to invest in and commercialize the next generation of patient flow and nurse communication solutions designed to enhance efficiency, improve patient safety and integrate communications within the health care environment. In addition, Hill-Rom and TeleTracking have established a joint sales and marketing arrangement to leverage the combined market reach of the two companies as they take patient flow and nurse communications solutions to market. As part of the agreement, TeleTracking purchased the assets of Hill-Rom's Patient Flow product line, thereby bringing the complete work flow solution into TeleTracking's software and service offerings. This arrangement will allow for each company to focus on and leverage its core competencies and support the companies' commitment to pursue initiatives and opportunities that leverage their combined strengths in delivering greater value to hospital customers.

Table of Contents

• We continue to work with our customers to offer and develop leasing and financing solutions that alleviate some of the capital pressure felt by U.S. hospitals and other health care organizations. These programs are designed to utilize our strong capital position and to provide our customers and patients access to Hill-Rom® technology earlier than might otherwise be possible under current conditions.

• As previously announced, we have continued to implement our plan to restore growth and improve the profitability of our Medical Equipment Management Services ("MEMS") business. Implementation of the plan has included a more strategic focus on customers, a limited rationalization in our service center footprint to align and consolidate resources and better serve our customers and the rationalization and disposal of select assets and asset groups. The implementation of this plan, along with the more aggressive management of capital expenditures, has resulted in improved gross margins and increased cash flows for this business, despite a planned reduction in revenue.

Achieve a Leadership Position in our Post-Acute Care Business.
• As we seek to increase our presence across the North America care continuum, we have made investments in new products, new business models and improved business systems that we believe will enable us to profitably participate in the large and growing Home Care and Extended Care segments. The Hill-Rom® 70 and 80 beds (Home Care and Extended Care) were recently launched and our long time frame leader, the Resident® Bed, was refreshed and re-launched. The addition of Liko™ products has also been well received in the Extended Care and Home Care segments through our indirect sales channels.

• Our Respiratory Care and Home Care business units have continued to grow. Changes made during fiscal 2008 in all businesses in terms of sales channel, product offering and account development have continued to deliver strong results on the bottom line. Respiratory Care continues to grow in additional Medicare covered disease states such as neuromuscular and our Home Care business continues to increase sales of products directly to consumers.

• We also continue to focus on process improvement with Six Sigma tools and training and process improvement events that are yielding bottom line results. Among a number of projects, we have initiated a project to move to document imaging that will be completed over the next two quarters and provide increased efficiency and effectiveness of our Third Party billing functions.

Expand our International and Surgical Business.
• We have continued to successfully leverage our existing European Acute Care sales channel capacity to maintain sales volume, despite capital spending pressures on our customers, as well as to integrate Liko™ patient lifts into our Acute and Post-Acute Care sales channel. Over the course of the year we have experienced volume increases, which have generally been offset by the negative impact of currency movements, while also improving operating margin.

• We have achieved incremental growth in under-penetrated regions and leveraged additional channel capacity. Through the end of the third quarter, we have begun to see the demand for frames and surfaces in selected regions, particularly in Asia and parts of Europe, be impacted by the global economic downturn. However, despite the recent downturn, we have experienced strong growth year-to-date in certain regions, particularly in Latin America and the Middle East and Africa.

Table of Contents

Improve Gross Margins and Realize Operating Expense Efficiencies.
• We continue to execute strategies to mitigate cost pressures and the impact of the global economic environment. We have various ongoing continuous improvement initiatives underway in our Batesville, Indiana and Pluvigner, France manufacturing facilities, and we also continue to focus on centralization of our global supply chain, and increased utilization of low cost region manufacturing and sourcing. As an example, implementation of a new universal manufacturing line in Pluvigner, France is complete and has provided greater than 20 percent improvements in labor productivity. We also have various workstreams aimed at a reduction in discretionary and operational spending that have resulted in significant reductions during the first nine months of our fiscal year.

• We have refined our strategies and plans for execution in research and development and innovation. We changed the top two layers of our organization early in the fiscal year to improve speed and execution. We have recently expanded our commitment and resources in Singapore, where we enjoy engineering cost advantage, including local government incentives. We have eliminated most of our outside temporary and contracted resources and brought the work inside, at a significant savings as well. We are also working much more extensively with outside development partners to share the development risk and increase our access to enabling technologies. These various initiatives have helped us to manage our costs while continuing to progress our technology platforming efforts. We believe we have a strong product pipeline that will improve sales momentum when normal buying patterns return.

• Margins in our rental business continue to accelerate due to the continuous improvement culture within our service fulfillment operations that has led to continued productivity gains. We have also achieved positive results from our customer partnering initiatives, which allow us to meet customer needs at a lower cost.

• Our Monterrey, Mexico facility continues to perform well with our first two product lines fully operational. Output during the current fiscal year has increased 65 percent versus output from the same period in 2008. Conversion costs on lines transferred to Monterrey versus pre-transfer levels are 50 percent better. Efforts continue to be focused on completion of supply base localization efforts as well as transition of the next product line into the Monterrey facility.

• During the third quarter, in an effort to streamline our manufacturing processes and leverage our existing U.S. manufacturing sites in Batesville, we completed the transition of certain surface and frames manufacturing from Charleston to Batesville. This transition has met or exceeded the related preestablished metrics.

• On January 14, 2009, we announced a plan to manage our cost structure through consolidation of certain manufacturing and selected back office operations; redeployment of U.S. sales and service resources to increase our customer presence and support; reduction in non-sales, non-research and development discretionary spending; a voluntary early retirement program, and involuntary job eliminations. These actions were completed during our third quarter and are expected to result in annual savings of $12 to $14 million. For additional information related to these actions, see Note 10 included in our Notes to Condensed Consolidated Financial Statements.

• During August of 2008, we completed a review of our organizational structure aimed at creating a more streamlined organization. This process resulted in the elimination of approximately 160 professional, salaried and non-exempt employee positions. The implementation of this restructuring plan was substantially completed by the end of our first fiscal quarter.

Table of Contents